Study finds risk of recurrence low in smallest HER2+ breast cancer tumors

[News]

Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a...

More... (http://www.medicalnewstoday.com/releases/277647.php)